Suárez GD, Domínguez CLG

Language: Spanish
References: 21
Page: 259-263
PDF size: 140.00 Kb.

ABSTRACT

Background: Gastrointestinal stromal tumors (GIST) have aroused interest in the development of molecular target therapy. More than 80% of the patients benefit from an inhibitor of tyrosine kinase, with an increased survival of five years. The adherence to treatment with imatinib is unknown in a specific population of patients with GIST. Objective: To measure the adherence to imatinib in patients with GIST and to know the factors by which it is influenced. Material and methods: Patients with GIST treated with imatinib, answering the Morisky-Green/Batalla questionnaire. Results: 84 patients met the inclusion criteria; of them, 41 (48.8%) showed a lack of adherence to the treatment; the most frequently detected factor was forgetting to take the drug, in 53% of the cases, as a statistically significant factor. No other relationship between factors such as gender, socioeconomic status, education, comorbidities, side effects and the lack of adherence to the treatment were found. Conclusions: Forgetting the drug intake is the main factor in the lack of adherence to treatment, and it is related to the patient’s ignorance of the effects caused by the suspension of the drug or an irregular intake, which depends on the explanation by the treating physician.

REFERENCES

1. Blay JY. New paradigms in gastrointestinal stromal tumour management. Ann Oncol. 2009; 20 Suppl 1: i18-i24.

2. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007; 369 (9574): 1731-1741.

3. Azcoitia-Moraila F. Tumores del estroma gastrointestinal, definición, generalidades y epidemiología. Cir Gen. 2008; 30 (S1): 5-10.

4. Blay JY. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev. 2011; 37 (5): 373-384.

5. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004; 22 (18): 3813-3825.

6. Poveda A, Artigas V, Casado A, Cervera J, García del Muro X, López-Guerrero JA et al. Guía de práctica clínica en los tumores estromales gastrointestinales (GIST). Cir Esp. 2008; 84 (Supl 1): 1-21.

7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23 (2): 70-83.

8. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231 (1): 51-58.

9. Ganjoo KN, Patel S. Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Drugs. 2011; 71 (3): 321-330.

10. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347 (7): 472-480.

11. Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002; 38 Suppl 5: S83-S87.

12. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007; 25 (9): 1107-1113.

13. Adenis A, Cassier PA, Bui BN, Rios M, Duffaud F, Bertucci F et al. Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial? J Clin Oncol. 2008; 26 Suppl 15: 10522-10522.

14. Feng W, Henk H, Thomas S, Baladi J, Hatfield A, Goldberg GA et al. Compliance and persistency with imatinib. J Clin Oncol. 2006; 24 Suppl 18: 6038.

15. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009; 27 (19): 3141-3147.

16. Bui BN, Italiano A, Miranova A, Bouchet S, Molimard M. Trough imatinib plasma levels in patients treated for advanced gastrointestinal stromal tumors evidence of large interpatient variations under treatment with standard doses. J Clin Oncol. 2008; 26 Suppl 15: 10564-10564.

17. von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev. 2011; 37 (4): 291-299.

18. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol. 2006; 24: 6119.

19. Rodríguez-Chamorro MA, García-Jiménez E, Amariles P, Rodríguez Chamorro A, Faus MJ. Revisión de tests de medición del cumplimiento terapéutico utilizados en la práctica clínica. Aten Primaria. 2008; 40 (8): 413-417.

20. García AM, Leiva F, Martos F, García AJ, Prados D, Sánchez et al. ¿Cómo diagnosticar el cumplimiento terapéutico en atención primaria? Medicina de Familia (And). 2000; 1 (1): 13-19.

21. Gutiérrez-Angulo ML, Lopetegi-Uranga P, Sánchez-Martín I, Garaigordobil-Landazabal M. Therapeutic compliance in patients with arterial hypertension and type 2 diabetes mellitus. Rev Calid Asist. 2012; 27 (2): 72-77.